Your browser is no longer supported. Please, upgrade your browser.
Settings
TYME Tyme Technologies, Inc. daily Stock Chart
TYME [NASD]
Tyme Technologies, Inc.
Index- P/E- EPS (ttm)-0.27 Insider Own42.30% Shs Outstand108.82M Perf Week-20.21%
Market Cap167.58M Forward P/E- EPS next Y-0.23 Insider Trans-0.48% Shs Float61.02M Perf Month50.98%
Income-28.60M PEG- EPS next Q-0.06 Inst Own12.00% Short Float11.64% Perf Quarter6.21%
Sales- P/S- EPS this Y-53.90% Inst Trans0.03% Short Ratio13.67 Perf Half Y33.91%
Book/sh0.07 P/B22.00 EPS next Y-15.00% ROA-149.50% Target Price8.50 Perf Year-33.91%
Cash/sh0.14 P/C10.95 EPS next 5Y- ROE-255.80% 52W Range0.92 - 3.42 Perf YTD10.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-54.97% Beta0.43
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin- 52W Low67.39% ATR0.17
Employees15 Current Ratio3.50 Sales Q/Q- Oper. Margin- RSI (14)49.46 Volatility10.72% 12.54%
OptionableYes Debt/Eq0.00 EPS Q/Q20.70% Profit Margin- Rel Volume0.39 Prev Close1.54
ShortableYes LT Debt/Eq0.00 EarningsFeb 10 AMC Payout- Avg Volume519.92K Price1.54
Recom- SMA20-5.11% SMA5018.72% SMA20018.15% Volume156,352 Change0.00%
Jan-27-20 08:00AM  Health Economic Research Study Demonstrates Increased Use of New Medicines in the Treatment of Patients with Pancreatic Cancer Reduces Total Cost of Care GlobeNewswire
Jan-16-20 08:00AM  TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas GlobeNewswire +12.07%
Jan-09-20 08:40AM  Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study Zacks
Jan-08-20 10:18AM  Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up Zacks
08:00AM  TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer GlobeNewswire
Jan-07-20 09:25AM  Tyme stock rises on Eage collaboration for cancer drug MarketWatch +13.64%
07:20AM  Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer Business Wire
Dec-30-19 11:17AM  Analysts: These 3 Strong Buy Penny Stocks Could Soar in 2020 TipRanks +13.33%
Dec-23-19 02:55PM  Hedge Funds Have Never Been More Bullish On Tyme Technologies, Inc. (TYME) Insider Monkey
Dec-12-19 02:14PM  Wall Street Suggests These Falling Knives GuruFocus.com
Dec-04-19 08:00AM  Tyme Technologies to Present at the 2019 Cross-Border Healthcare Winter Summit in New York GlobeNewswire
Nov-25-19 08:00AM  TYME to Ring Nasdaq Opening Bell on November 27 to Honor All Stakeholders Committed to Finding a Cure for Patients with Pancreatic Cancer GlobeNewswire
Nov-21-19 08:00AM  Tyme Technologies to Present at the Evercore ISI HealthCONx Conference 2019 GlobeNewswire +15.24%
Nov-07-19 08:00AM  Tyme Technologies to Present at Jefferies 2019 London Healthcare Conference on November 20-21, 2019 GlobeNewswire
Nov-04-19 04:05PM  TYME Presents Business Update and Reports Second Quarter Fiscal 2020 Financial and Operating Results GlobeNewswire
Oct-17-19 04:05PM  TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results GlobeNewswire
11:24AM  Lilly's Pancreatic Cancer Candidate Fails in Phase III Study Zacks
Oct-03-19 01:36PM  How Much Are Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Taking Off The Table? Simply Wall St.
Oct-01-19 08:00AM  TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer GlobeNewswire +6.30%
Sep-30-19 08:00AM  TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer GlobeNewswire -20.13%
Sep-26-19 11:16AM  Tyme Initiates Pivotal Stage of Pancreatic Cancer Study Zacks -6.56%
Sep-25-19 08:00AM  TYME Launches Pivotal Stage of TYME-88-PANC Trial to Evaluate SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer GlobeNewswire
Sep-17-19 08:00AM  Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019 GlobeNewswire
Sep-09-19 09:26AM  Will Tyme Technologies Continue to Surge Higher? Zacks +8.80%
08:00AM  TYME Presents Positive Circulating Tumor Cell Data from TYME-88-Panc Study in Patients with Advanced Pancreatic Cancer at AACR PANC 2019 GlobeNewswire
Sep-04-19 08:00AM  Tyme Technologies to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright on September 9, 2019 GlobeNewswire
Aug-12-19 08:00AM  TYME Announces Abstracts Selected for Presentation at the European Society of Medical Oncology Congress 2019 GlobeNewswire
Aug-09-19 08:00AM  Tyme Technologies to Present at BTIG Biotechnology Conference on August 12th, 2019 GlobeNewswire
Aug-08-19 08:00AM  TYME Provides Business Update and Reports First Quarter Fiscal 2020 Financial and Operating Results GlobeNewswire
Aug-07-19 08:00AM  TYME Announces Abstracts Selected for Presentation at the AACR Special Conference on Pancreatic Cancer GlobeNewswire
Aug-01-19 08:00AM  Tyme Technologies to Present at the 39th Annual Canaccord Genuity Growth Conference on August 7th, 2019 GlobeNewswire
Jul-29-19 08:00AM  TYME Technologies Announces New Collaboration with NYU Langone to Advance TYMEs Cancer Metabolism-Based Therapy, SM-88 GlobeNewswire
Jul-08-19 08:00AM  REMINDER - TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer GlobeNewswire
Jul-05-19 12:41PM  Tyme Technologies News: Why TYME Stock Is Rocketing InvestorPlace +18.85%
09:46AM  Tyme Technologies stock soars on heavy volume after upbeat update to cancer treatment study MarketWatch
08:00AM  TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer GlobeNewswire
Jun-27-19 03:48PM  Will Tyme Technologies, Inc.'s (NASDAQ:TYME) Earnings Grow Over The Next Few Years? Simply Wall St. +9.90%
Jun-23-19 11:35AM  Weekly CFO Buys Highlight GuruFocus.com
Jun-07-19 08:00AM  TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019 GlobeNewswire
May-29-19 07:30AM  TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results GlobeNewswire -9.23%
May-28-19 08:31AM  The Tyme Technologies (NASDAQ:TYME) Share Price Is Down 83% So Some Shareholders Are Rather Upset Simply Wall St. -5.80%
08:00AM  Tyme Technologies to Present at the Jefferies 2019 Global Healthcare Conference on June 7, 2019 GlobeNewswire
May-24-19 08:00AM  Tyme Technologies To Host a Conference Call for the Fourth Quarter and Fiscal Year 2019 Financial and Operating Results on May 29, 2019 GlobeNewswire
May-23-19 08:00AM  TYME and The Joseph Ahmed Foundation Announce Initiation of the HopES Phase II Trial Evaluating the Potential Benefits of SM-88 for Patients with High-Risk Sarcomas GlobeNewswire
May-20-19 08:00AM  TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers GlobeNewswire
May-09-19 08:00AM  Tyme Technologies to Participate at the Oppenheimer Oncology Insight Summit on May 16th GlobeNewswire +9.68%
May-02-19 08:00AM  Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019 GlobeNewswire
May-01-19 08:00AM  Tyme Technologies to Participate at the SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on May 7th GlobeNewswire
Apr-15-19 08:00AM  TYME Announces USAN Approval of Generic Name Racemetyrosine for SM-88 GlobeNewswire -6.82%
Apr-08-19 08:00AM  TYMEs SM-88 First Human Study in Patients with Metastatic Cancer Published in the Journal, Investigational New Drugs GlobeNewswire +5.03%
Apr-03-19 08:00AM  TYME Secures Capital to Advance Pivotal Studies of SM-88 in Metastatic Pancreatic Cancer GlobeNewswire -5.95%
Apr-01-19 08:00AM  TYME Announces Dismissal of Class Action Lawsuit GlobeNewswire +7.39%
Mar-29-19 08:00AM  Tyme Technologies Announces Pricing of its $12 Million Registered Offering GlobeNewswire -10.66%
Mar-28-19 04:58PM  SHAREHOLDER ALERT: VALE TYME UXIN UMC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire +5.35%
04:25PM  DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:57PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline TYME GlobeNewswire
11:15AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of TYME, GE and AVP ACCESSWIRE
Mar-27-19 10:55PM  2-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE -10.10%
12:45PM  CLASS ACTION UPDATE for ZIV, TYME and UMC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:28AM  Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action ACCESSWIRE
10:00AM  Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) GlobeNewswire
Mar-26-19 05:02PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of VALE, TYME, MHLD and BPI GlobeNewswire
04:40PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tyme Technologies, Inc. To Contact The Firm ACCESSWIRE
04:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline - TYME ACCESSWIRE
03:15PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TYME, TAP, KHC and SYNH GlobeNewswire
02:52PM  TYME MARCH 29 DEADLINE: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Tyme Technologies, Inc. TYME GlobeNewswire
Mar-22-19 03:10PM  SHAREHOLDER ALERT: ARLO TYME AVP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE -8.85%
12:26PM  DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
12:08PM  CLASS ACTION UPDATE for TYME, GE and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:39AM  Class Action Reminder GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Mar-21-19 03:45PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of TYME, SVXY, AMR and MBT GlobeNewswire
03:00PM  Class Action Reminder GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
01:15PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TYME, UMC and BPI ACCESSWIRE
Mar-20-19 09:03PM  Pawar Law Group Reminds Investors of  March 29 Deadline in Securities Class Action Lawsuit Against Tyme Technologies, Inc. TYME GlobeNewswire
02:48PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tyme Technologies, Inc. To Contact The Firm GlobeNewswire
01:09PM  SHAREHOLDER ALERT: GSM TYME AMR CNDT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
10:38AM  GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder ACCESSWIRE
09:37AM  CLASS ACTION UPDATE for TYME, KHC, DPLO and CTL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Mar-19-19 06:40PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline TYME ACCESSWIRE
05:05PM  CLASS ACTION UPDATE for TYME, VNDA and CNDT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
04:16PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Tyme Technologies, Inc. to Contact the Firm Business Wire
Mar-18-19 11:57AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, TYME, TAP and UMC GlobeNewswire
10:36AM  GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC Class Action ACCESSWIRE
08:00AM  TYME Announces Leadership Team Update GlobeNewswire
Mar-17-19 11:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SPB, TYME and STMP ACCESSWIRE
Mar-16-19 07:15PM  EQUITY ALERT: Rosen Law Firm Reminds Tyme Technologies, Inc. Investors of Important Deadline in Securities Class Action Lawsuit TYME GlobeNewswire
Mar-15-19 09:50PM  7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
11:46AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of TYME, DPLO, CVS and SYNH GlobeNewswire
Mar-14-19 08:56PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline TYME GlobeNewswire
03:25PM  CLASS ACTION UPDATE for TYME, AMRN and CVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
03:00PM  (TYME) Tyme Technologies, Inc. - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder & Final Deadline March 29, 2019 GlobeNewswire
10:52AM  GSM, TYME & VALE Bronstein, Gewirtz & Grossman, LLC Class Action ACCESSWIRE
Mar-13-19 03:28PM  CLASS ACTION UPDATE for TYME, AVEO, CVS and CTL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire +6.48%
10:55AM  (TYME) Tyme Technologies, Inc. - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder & Final Deadline March 29, 2019 ACCESSWIRE
10:17AM  SHAREHOLDER ALERT: MAXR MU TYME TAP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Mar-12-19 08:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline TYME ACCESSWIRE
06:01PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ARLO, ATVI, MU and TYME GlobeNewswire
04:00PM  CLASS ACTION UPDATE for ARLO, TYME, KHC and SYNH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
03:43PM  TYME DEADLINE ALERT: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Tyme Technologies, Inc. TYME GlobeNewswire
10:55AM  (TYME) Tyme Technologies, Inc. - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder & Final Deadline Alert March 29, 2019 ACCESSWIRE
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in Phase II clinical trials to treat cancer, including pancreatic, lung, breast, prostate, and sarcoma cancers. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Demurjian Michael10% OwnerJan 27Sale1.5220,00030,35025,010,521Jan 28 09:19 AM
Demurjian Michael10% OwnerJan 21Sale1.9020,00037,90025,030,521Jan 22 04:27 PM
Demurjian Michael10% OwnerJan 13Sale1.6420,00032,80025,050,521Jan 14 08:43 AM
Demurjian Michael10% OwnerJan 06Sale1.4720,00029,32025,070,521Jan 07 04:37 PM
Demurjian Michael10% OwnerDec 30Sale1.0720,00021,44825,090,521Dec 31 08:49 AM
Demurjian Michael10% OwnerDec 23Sale0.9720,00019,45226,010,521Dec 23 05:23 PM
Demurjian Michael10% OwnerDec 16Sale1.0520,00020,94226,030,521Dec 18 09:26 AM
Demurjian Michael10% OwnerDec 09Sale1.0820,00021,61026,050,521Dec 09 05:41 PM
Demurjian Michael10% OwnerDec 02Sale1.1420,00022,86826,070,521Dec 03 04:44 PM
Demurjian Michael10% OwnerNov 25Sale1.1320,00022,56426,090,521Nov 25 04:50 PM
Demurjian Michael10% OwnerNov 18Sale1.0020,00020,00026,110,521Nov 19 04:38 PM
Hoffman SteveChief Executive OfficerNov 15Buy1.0310,00010,30026,492,748Nov 18 04:13 PM
Biehl JamesChief Legal OfficerNov 15Buy1.0510,00010,50045,000Nov 18 04:11 PM
Demurjian Michael10% OwnerNov 11Sale1.1620,00023,27426,130,521Nov 12 03:39 PM